Amid Biotech Swoon, Third Rock’s MyoKardia Tees up IPO
Does the biotech bull market still have a pulse? MyoKardia, a three-year-old startup developing heart drugs, will soon try to find out.
The San Francisco-based company filed papers with the SEC on Monday to go public and trade on the Nasdaq under the ticker symbol “MYOK.” MyoKardia would use the cash to advance its work in drugs for certain forms of genetically triggered heart disease, like hypertrophic cardiomyopathy (HCM). And it’ll ask investors to buy into a company without a whole lot of clinical data as of yet—the first of its prospects, a drug known as MYK-461, is in Phase 1 tests that are expected to wrap up in the middle of next year.